These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32579403)

  • 21. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
    Yamamoto T; Shiraki M; Bamba T; Umegae S; Matsumoto K
    Int J Colorectal Dis; 2014 Apr; 29(4):485-91. PubMed ID: 24343276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET/MRI for evaluating subclinical inflammation of ulcerative colitis.
    Shih IL; Wei SC; Yen RF; Chang CC; Ko CL; Lin BR; Shun CT; Liu KL; Wong JM; Chang YC
    J Magn Reson Imaging; 2018 Mar; 47(3):737-745. PubMed ID: 28640521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
    Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
    Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.
    D'Incà R; Dal Pont E; Di Leo V; Ferronato A; Fries W; Vettorato MG; Martines D; Sturniolo GC
    Int J Colorectal Dis; 2007 Apr; 22(4):429-37. PubMed ID: 16838143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
    Burri E; Beglinger C; von Felten S; Lehmann FS
    Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn's Disease: A Pilot Study.
    Domachevsky L; Leibovitzh H; Avni-Biron I; Lichtenstein L; Goldberg N; Nidam M; Groshar D; Bernstine H; Ben-Bassat O
    Contrast Media Mol Imaging; 2017; 2017():7167292. PubMed ID: 29097934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
    Stragier E; Van Assche G
    Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT.
    Louis E; Ancion G; Colard A; Spote V; Belaiche J; Hustinx R
    J Nucl Med; 2007 Jul; 48(7):1053-9. PubMed ID: 17574978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
    Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
    J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study.
    Jauregui-Amezaga A; López-Cerón M; Aceituno M; Jimeno M; Rodríguez de Miguel C; Pinó-Donnay S; Zabalza M; Sans M; Ricart E; Ordás I; González-Suárez B; Cuatrecasas M; Llach J; Panés J; Pellise M
    Inflamm Bowel Dis; 2014 Jul; 20(7):1187-93. PubMed ID: 24874457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Performance of Simultaneous [
    Langhorst J; Umutlu L; Schaarschmidt BM; Grueneisen J; Demircioglu A; Forsting M; Beiderwellen K; Haubold J; Theysohn JM; Koch AK; Dobos G; Dechêne A; Herrmann K; Bruckmann NM; Lauenstein T; Li Y
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32752196
    [No Abstract]   [Full Text] [Related]  

  • 38. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
    Frin AC; Filippi J; Boschetti G; Flourie B; Drai J; Ferrari P; Hebuterne X; Nancey S
    Dig Liver Dis; 2017 Jan; 49(1):11-16. PubMed ID: 27693318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.